Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

Therapeutic drug monitoring is an important tool for managing patients with inflammatory bowel disease. In this test-specific episode of the "Answers From the Lab" podcast, Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood to better guide optimal treatment.

Mayo Clinic was the first laboratory to offer clinical quantitation of risankizumab, using a mass spectrometry test (Mayo ID: RISA). The new panel (Mayo ID: RISAP) includes that test in parallel with a unique bridging immunoassay for anti-risankizumab antibodies.

"Correlating those two results can really help physicians optimize treatment for each individual patient," Dr. Snyder says. "It allows for more appropriate dosing, and evaluates for the potential application of immune modulators or for whether another drug might be more appropriate."

The new immunoassay is the only risankizumab antibody test currently available. RISAP is recommended when physicians suspect loss of response to risankizumab therapy. "Therapeutic drug monitoring of biologics has become standard of care in gastroenterology, especially in the inflammatory bowel disease space," Dr. Willrich says.

Listen to learn more about Mayo Clinic Laboratories' new RISAP panel.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

RISAP | Risankizumab Quantitation with Antibodies, Serum

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less